Literature DB >> 15486926

Occult hepatitis B virus infection in a North American adult hemodialysis patient population.

Gerald Y Minuk1, Dong Feng Sun, Rebecca Greenberg, Manna Zhang, Kimberly Hawkins, Julia Uhanova, Adam Gutkin, Kevin Bernstein, Antonio Giulivi, Carla Osiowy.   

Abstract

Hepatitis B virus (HBV) infections continue to occur in adult hemodialysis units. A possible contributing factor is the presence of occult HBV (serum hepatitis B surface antigen [HBsAg] negative but HBV DNA positive). Two hundred forty-one adult hemodialysis patients were screened for occult HBV. HBV DNA testing was performed by real-time polymerase chain reaction (PCR) with 2 independent primer sets (core promoter and surface). Two (0.8%) of the 241 patients were HBsAg positive. Of the remaining 239 HBsAg-negative patients, 9 (3.8%) were HBV DNA positive. Viral loads in these individuals were low (10(2)-10(4) viral copies/mL). Seven of the 9 (78%) were nt 587 mutation (sG145R mutant) positive. Demographic, biochemical, and HBV serological testing did not help to identify those with occult HBV. In conclusion, the prevalence of occult HBV in adult hemodialysis patients in this North American urban center is approximately 4 to 5 times higher than standard HBsAg testing would suggest. The majority of these infections are associated with low viral loads and a high prevalence of the sG145R mutant. Finally, the demographic, biochemical, and/or serological features of HBV DNA-positive subjects do not distinguish these individuals from the remainder of the dialysis patient population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486926     DOI: 10.1002/hep.20435

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

1.  Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?

Authors:  Mehmet Kanbay; Gurden Gur; Ali Akcay; Haldun Selcuk; Ugur Yilmaz; Hande Arslan; Sedat Boyacioglu; Fatma Nurhan Ozdemir
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

Review 2.  Genetic variation of occult hepatitis B virus infection.

Authors:  Hui-Lan Zhu; Xu Li; Jun Li; Zhen-Hua Zhang
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

4.  False-negative hepatitis B virus (HBV) surface antigen in a vaccinated dialysis patient with a high level of HBV DNA in the United States.

Authors:  Matthew C Foy; Chloe L Thio; Hyon S Hwang; Melissa Saulynas; James P Hamilton; Derek M Fine; Mohamed G Atta
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

5.  Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.

Authors:  Ozcan Ceneli; Zübeyde Nur Ozkurt; Kadir Acar; Seyyal Rota; Sahika Zeynep Aki; Zeynep-Arzu Yeğin; Münci Yağci; Seren Ozenirler; Gülsan Türköz Sucak
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

Review 6.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

7.  Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

8.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

9.  Hepatitis B and Renal Disease.

Authors:  Tak Mao Chan
Journal:  Curr Hepat Rep       Date:  2010-04-14

10.  Molecular characteristics of occult hepatitis B virus from blood donors in southeast China.

Authors:  Quan Yuan; Shan-Hai Ou; Chang-Rong Chen; Sheng-Xiang Ge; Bin Pei; Qing-Rui Chen; Qiang Yan; Yong-Cai Lin; Hong-Ying Ni; Cheng-Hao Huang; Anthony E T Yeo; James W K Shih; Jun Zhang; Ning-Shao Xia
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.